Breakout Stocks   Corona Virus Stocks  

Added To Russell 3000(R) And Russell Microcap(R) Indexes – Strong Buy $4.00 Target By Maxim Research

These shares are ready to soar and on track to take out its first major target price of $4.00. Above that level there are no significant resistance levels . This biomed technology and research company has come alive and with its pockets filled with cash from a recent $14 million offering , the company will rapidly move forward executing its business model driving these shares significantly higher

Watch This You Tube Video Interview On Cather Placement In The Spine

Additionally MLSS was recently added to two important indexes giving much added retail and institutional visibility. All the planets are aligned for these shares . 

Epidural Proves Deadly In NY Hospital – Milestone Scientific Has Solution . Maxim Group  $4.00 Target –

We urge all serious investors to place these shares immediately on their BUY LIST

CEO Webinar  Red Chip CEO Interview

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications.


Milestone Scientific Added to Russell 3000(R) and Russell Microcap(R) Indexes

ROSELAND, NJ / ACCESSWIRE / June 29, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has been added to the Russell 3000® and Russell Microcap® Indexes, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.


Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. We have been paid $1500 to write this article